Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)

医学 特应性皮炎 随机对照试验 皮肤病科 外科
作者
Eric L. Simpson,Seth Forman,Jonathan I. Silverberg,Matthew Zirwas,Emanual Maverakis,George Han,Emma Guttman‐Yassky,Daniel Marnell,Robert Bissonnette,Jill Waibel,Fabio P. Nunes,Amy M. DeLozier,Robinette Angle,Margaret Gamalo,Katrin Holzwarth,Orin M. Goldblum,Jinglin Zhong,Jonathan Janes,Kim Papp
出处
期刊:Journal of The American Academy of Dermatology [Elsevier BV]
卷期号:85 (1): 62-70 被引量:137
标识
DOI:10.1016/j.jaad.2021.02.028
摘要

Background Baricitinib, an oral selective Janus kinase 1/Janus kinase 2 inhibitor, is being studied for moderate-to-severe atopic dermatitis (AD) in adults. Objective To evaluate the efficacy and safety of baricitinib monotherapy in a North American phase 3 trial (BREEZE-AD5/NCT03435081) of adults with moderate-to-severe AD who responded inadequately or were intolerant to topical therapy. Methods Patients (N = 440) were randomized 1:1:1 to once-daily placebo or baricitinib (1 mg or 2 mg). The primary endpoint was the proportion of patients achieving ≥75% reduction in the Eczema Area and Severity Index at week 16. A key secondary endpoint was the proportion of patients achieving a validated Investigator Global Assessment for AD score of 0 (clear)/1(almost clear) with ≥2-point improvement. Results At week 16, the proportion of patients achieving Eczema Area and Severity Index was 8%, 13%, and 30% (P < .001, 2 mg vs placebo) and those with a validated Investigator Global Assessment for AD score of 0/1 were 5%, 13%, and 24% (P < .001, 2 mg vs placebo) for placebo, baricitinib 1 mg, and baricitinib 2 mg, respectively. Safety findings were similar to those of other baricitinib AD studies. Limitations Short-term clinical trial results may not be generalizable to real-world settings. Conclusion Baricitinib was efficacious for patients with moderate-to-severe AD with no new safety findings over 16 weeks. Baricitinib, an oral selective Janus kinase 1/Janus kinase 2 inhibitor, is being studied for moderate-to-severe atopic dermatitis (AD) in adults. To evaluate the efficacy and safety of baricitinib monotherapy in a North American phase 3 trial (BREEZE-AD5/NCT03435081) of adults with moderate-to-severe AD who responded inadequately or were intolerant to topical therapy. Patients (N = 440) were randomized 1:1:1 to once-daily placebo or baricitinib (1 mg or 2 mg). The primary endpoint was the proportion of patients achieving ≥75% reduction in the Eczema Area and Severity Index at week 16. A key secondary endpoint was the proportion of patients achieving a validated Investigator Global Assessment for AD score of 0 (clear)/1(almost clear) with ≥2-point improvement. At week 16, the proportion of patients achieving Eczema Area and Severity Index was 8%, 13%, and 30% (P < .001, 2 mg vs placebo) and those with a validated Investigator Global Assessment for AD score of 0/1 were 5%, 13%, and 24% (P < .001, 2 mg vs placebo) for placebo, baricitinib 1 mg, and baricitinib 2 mg, respectively. Safety findings were similar to those of other baricitinib AD studies. Short-term clinical trial results may not be generalizable to real-world settings. Baricitinib was efficacious for patients with moderate-to-severe AD with no new safety findings over 16 weeks.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小机灵鬼发布了新的文献求助10
刚刚
小王完成签到,获得积分10
刚刚
3秒前
3秒前
奥氏发布了新的文献求助10
3秒前
做错了范完成签到,获得积分10
3秒前
Mint发布了新的文献求助10
4秒前
4秒前
lishaokun查文献完成签到 ,获得积分10
4秒前
荔枝味发布了新的文献求助10
4秒前
zww发布了新的文献求助10
5秒前
5秒前
dumeng完成签到,获得积分20
7秒前
8秒前
敏感思远发布了新的文献求助10
8秒前
8秒前
9秒前
汉堡包的应助被害怕的奇异果采纳,获得10
9秒前
10秒前
10秒前
10秒前
10秒前
散人发布了新的文献求助10
10秒前
清秀语蝶的应助被wsdmn采纳,获得10
11秒前
liu发布了新的文献求助10
11秒前
12秒前
ff完成签到,获得积分10
12秒前
黎叔叔发布了新的文献求助30
12秒前
姜盐豆子茶完成签到 ,获得积分10
12秒前
炒鸡战斗机完成签到,获得积分10
13秒前
13秒前
14秒前
Wenky完成签到 ,获得积分10
14秒前
一颗葡萄完成签到 ,获得积分10
14秒前
慕青的应助被123采纳,获得10
14秒前
汉堡包的应助被奥氏采纳,获得10
14秒前
赘婿的应助被SYF采纳,获得10
15秒前
酷波er的应助被CQNU破产之人采纳,获得10
15秒前
WeiJia发布了新的文献求助10
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172327
求助须知:如何正确求助?哪些是违规求助? 9564990
关于积分的说明 21777687
捐赠科研通 7763968
什么是DOI,文献DOI怎么找? 3431223
关于科研通互助平台的介绍 2555098
邀请新用户注册赠送积分活动 2476246